Affordable Access

Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.

Authors
  • Neijt, J P
  • ten Bokkel Huinink, W W
  • van der Burg, M E
  • van Oosterom, A T
  • Vriesendorp, R
  • Kooyman, C D
  • van Lindert, A C
  • Hamerlynck, J V
  • van Lent, M
  • van Houwelingen, J C
Type
Published Article
Journal
Lancet (London, England)
Publication Date
Sep 15, 1984
Volume
2
Issue
8403
Pages
594–600
Identifiers
PMID: 6147640
Source
Medline
License
Unknown

Abstract

186 patients with advanced epithelial ovarian carcinoma were treated with either a combination of hexamethylmelamine, cyclophosphamide, methotrexate, and 5-fluorouracil (Hexa-CAF) or cyclophosphamide and hexamethylmelamine alternating with doxorubicin and a 5-day course of cisplatin (CHAP-5). Treatment with CHAP-5 resulted in more complete remissions as determined by laparatomy or peritoneoscopy (p = 0.004), better overall response (p = 0.0001), and longer overall survival and progression-free survival (p less than 0.002). Therapy, histological grade, and Karnofsky index were reliable predictors of overall response, whereas therapy, FIGO-stage, and size of residual tumour before chemotherapy were independent predictors for complete remission and for prolonged survival. Peripheral neurotoxicity was a major problem in patients assigned to the CHAP-5-group and was likely to be due to the simultaneous administration of hexamethylmelamine and cisplatin. The CHAP-5 regimen is one of the most effective regimens for the initial treatment of ovarian cancer.

Report this publication

Statistics

Seen <100 times